These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 3105322)

  • 1. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases.
    Sheibani K; Winberg CD; van de Velde S; Blayney DW; Rappaport H
    Am J Pathol; 1987 Apr; 127(1):27-37. PubMed ID: 3105322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell-rich lymphoproliferative disorders. Morphologic and immunologic differential diagnoses.
    Winberg CD; Sheibani K; Burke JS; Wu A; Rappaport H
    Cancer; 1988 Oct; 62(8):1539-55. PubMed ID: 2901904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases.
    Strauchen JA; Breakstone BA
    Am J Pathol; 1987 Mar; 126(3):506-12. PubMed ID: 3103454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
    Carbone A; Gloghini A; Gruss HJ; Pinto A
    Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leu-22: a preferential marker for T-lymphocytes in paraffin sections. Staining profile in T- and B-cell lymphomas, Hodgkin's disease, other lymphoproliferative disorders, myeloproliferative diseases, and various neoplastic processes.
    Said JW; Stoll PN; Shintaku P; Bindl JM; Butmarc JR; Pinkus GS
    Am J Clin Pathol; 1989 May; 91(5):542-9. PubMed ID: 2785753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
    Dorfman DM; Shahsafaei A
    Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistologic cellular phenotypes of lymphoproliferative disorders. Comprehensive evaluation of 564 cases including 257 non-Hodgkin's lymphomas classified by the International Working Formulation.
    Tubbs RR; Fishleder A; Weiss RA; Savage RA; Sebek BA; Weick JK
    Am J Pathol; 1983 Nov; 113(2):207-21. PubMed ID: 6605690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Tac antigen by non-Hodgkin's lymphomas.
    Weiss LM; Michie SA; Medeiros LJ; Strickler JG; Garcia CF; Warnke RA
    Am J Clin Pathol; 1987 Oct; 88(4):483-5. PubMed ID: 2821794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodal Involvement by CD30
    Lezama LS; Gratzinger D
    Arch Pathol Lab Med; 2018 Jan; 142(1):139-142. PubMed ID: 29257929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas.
    Weiss LM; Crabtree GS; Rouse RV; Warnke RA
    Am J Pathol; 1985 Feb; 118(2):316-24. PubMed ID: 3155915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma.
    Timens W; Visser L; Poppema S
    Lab Invest; 1986 Apr; 54(4):457-61. PubMed ID: 3083157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD 25 (Tac antigen) in lymphoid leukemias and non-Hodgkin lymphomas.
    Faure GC; Bene MC; Bolle-Chanal MH
    Eur J Haematol; 1987 Jan; 38(1):26-30. PubMed ID: 3034662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clusterin expression in malignant lymphomas: a survey of 266 cases.
    Saffer H; Wahed A; Rassidakis GZ; Medeiros LJ
    Mod Pathol; 2002 Nov; 15(11):1221-6. PubMed ID: 12429802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Tac antigen in B cell lymphomas.
    Laurent G; Al Saati T; Olive D; Laurent JC; Poncelet P; Delsol G
    Clin Exp Immunol; 1986 Aug; 65(2):354-62. PubMed ID: 3024885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-lymphocyte subpopulations in B-cell-derived non-Hodgkin's lymphomas and Hodgkin's disease.
    Knowles DM; Halper JP; Jakobiec FA
    Cancer; 1984 Aug; 54(4):644-51. PubMed ID: 6234982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotypic immunoglobulin secretion by human B cell non-Hodgkin's lymphomas is related to the expression of the interleukin-2 receptor.
    Vyth-Dreese FA; Dellemijn TA; Hekman A; Melief CJ
    Leukemia; 1988 Apr; 2(4):231-5. PubMed ID: 3129622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic value of immunohistological bone marrow examination: results in 212 patients with lymphoproliferative disorders.
    Thaler J; Denz H; Gattringer C; Glassl H; Lechleitner M; Dietze O; Huber H
    Blut; 1987 Apr; 54(4):213-22. PubMed ID: 3103722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.
    van den Berg A; Visser L; Poppema S
    Am J Pathol; 1999 Jun; 154(6):1685-91. PubMed ID: 10362793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathology of non-Hodgkin lymphomas.
    Huber H; Gattringer C; Knapp W; Stein H
    Klin Wochenschr; 1984 Nov; 62(21):1001-10. PubMed ID: 6392723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.